An innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides

An innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides

Abstract Background Receptors specific for the sugar N-acetylgalactosamine (GalNAc) include the human type II, C-type lectin receptor macrophage galactose-type lectin/C-type lectin receptor family member 10A (MGL/CLEC10A/CD301) that is expressed prominently by human peripheral immature dendritic cel...

Full description

Bibliographic Details
Main Authors: Laura L. Eggink, Katherine F. Roby, Robert Cote, J. Kenneth Hoober
Format: Article
Language:English
Published: BMJ Publishing Group 2018-04-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Glycomimetic peptides
Dendritic cells
CLEC10A
ASGPR-1
N-Acetylgalactosamine
Peritoneal cells
Online Access:http://link.springer.com/article/10.1186/s40425-018-0339-5

Internet

http://link.springer.com/article/10.1186/s40425-018-0339-5

Similar Items